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The case
Our patient is a 73-year-old African-
American lady who has had several hos-
pital admissions over the past 2 years 
with the diagnosis of Congestive Heart 
Failure (CHF). The patient was on home 
oxygen therapy for CHF and coumadin 
therapy for atrial fibrillation. In Septem-
ber 2005 the patient suddenly worsened 
with severe and progressive shortness 
of breath (SOB) and increasing leg 
edema. Her weight increased from 72.5 
kg to 113 kg and she became immo-
bile. A 2-D echocardiogram revealed 
an ejection fraction (EF) of 55%, para-
doxical septal motion with right ven-
tricular overload, severe right atrial and 
ventricular dilatation, severe tricuspid 
regurgitation, mild-to-moderate pulmo-
nary insufficiency, right ventricular (RV) 
end-diastolic pressure of  75 mmHg and 
severe pulmonary hypertension of 80 
mmHg. She was stabilized with diuretics 
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and sent home. On recurrence of her 
symptoms she presented to our hospital 
in November 2005. 
 The patient had extreme dyspnea with 
swelling of the legs, thighs and abdo-
men. Her vital signs were stable. Physi-
cal exam of the cardiac and respiratory 
systems showed a significantly elevat-
ed jugular venous distention of 14 cm, 
bilateral bibasilar crackles, reduced air 
entry, an irregular heart-beat with a nor-
mal S1 and a fixed split S2, a 2/6 to 3/6 
holo-systolic murmur (radiating through 
the whole precordium and changing 
with respiration), a laterally displaced 
point of maximal impulse and a right 
ventricle heave. The abdomen showed 
significant pulsatile hepatomegaly. The 
extremities had 4+ edema with chronic 
skin changes. Shotty adenopathy was 
seen in the cervical area and in the 
left supraclavicular area. Computed 
Axial Tomography (CAT) scan of the 
abdomen and pelvis showed abdomi-
nal ascites, small bilateral pleural 
effusions with pleural scarring, focal 
aneurysms and dilatation of the splenic 
artery measuring up to 3 cm in size and 
dense calcification and granulomatous 
changes of the spleen. Electrocardi-
ogram (ECG) showed normal sinus 
rhythm, incomplete right bundle branch 
block, T wave inversion in V1, V2, and 
V3 and RV hypertrophy.   
          We attempted to find the etiology 
of pulmonary hypertension and isolated 
right heart failure in this patient. There 
was no CAT scan evidence for chronic 
thrombo-embolic pulmonary disease 
or chronic obstructive pulmonary dis-
ease. A trans-esophageal echocardio-
gram (TEE) confirmed the echocar-
diogram findings and also revealed a 
possibility of patent foramen ovale. An 
extensive workup for Connective Tis-
sue Disease explaining the pulmonary 
hypertension was non-diagnostic. A 
Sleep study showed only mild sleep 
apnea. The calcifications in the spleen 
could not be explained, as there was 
no old evidence of either sarcoid or 
histoplasmosis or old tuberculosis on 
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the imaging studies. Chronic fibrosing 
mediastinitis could be the only cause 
of the calcifications that could explain 
the significant right-sided heart failure. 
Other differential diagnoses entertained 
were vasculitis, amyloidosis and multi-
ple myeloma.
Serum and urine protein electrophore-
sis with immunofixation revealed IgA 
gammopathy with normal IgM and IgG. 
The tests showed IgA lambda M-pro-
tein spike of 1900 mg/dl, IgG 1252 mg/
dl (normal range 620-1400 mg/dl), IgM 
179 mg/dl (normal range 45-250 mg/dl) 
and IgA 963 mg/dl (normal range 80-
350 mg/dl). Gamma globulin was 1.9 
gm/dl (normal range 0.7-1.6 gm/dl). 
With the possibility of amyloidosis as 
a cause for the patient’s symptoms, it 
was decided to biopsy the supraclavic-
ular adenopathy but the patient refused 
this procedure. Bone marrow biopsy 
was not done due to the patient’s poor 
status. The patient continued to have 
increasing respiratory distress and 
hypoxia despite medical treatment. She 
was made a Do-Not-Resuscitate (DNR) 
patient and expired in a nursing home 
in a few days. 
Amyloidosis
Introduction
Amyloidosis is a disorder character-
ized by the deposition of amorphous, 
extracellular insoluble fibrillar protein 
in various tissues of our body caus-
ing widespread organ dysfunction and 
death (1). There are different types of 
subunit proteins – mainly AL and AA. 
AL is derived from the light chain of 
a monoclonal immunoglobulin and is 
seen in both primary and myeloma 
amyloidosis. AA is seen in secondary 
amyloidosis associated with chronic 
inflammatory diseases such as renal 
disease, syphilis, inflammatory bowel 
disease, rheumatoid arthritis, bron-
chiectasis, leprosy, osteomyelitis and 
certain cancers (2). End-stage renal 
disease and dialysis is associated with 
B-2 M amyloid and familial or senile 
amyloidosis show ATTR (transthyre-
tin) amyloid. All amyloids bind Congo 
red, produce apple green birefringence 
under polarized light and have a b-
pleated structure. 
Incidence
Immunoglobulin amyloidosis is rare 
with an incidence of 8 patients per mil-
lion persons a year (3). 99% of patients 
are above the age of 40 years. (2)  
Diagnosis
The initial screening is with immuno-
electrophoresis and immunofixation 
of the serum and urine (4) revealing 
a monoclonal light chain in 90% of 
patients (5). In the rest, a subcutane-
ous fat aspirate, bone marrow biopsy 
or biopsies of the minor salivary glands 
will detect amyloid in 70-90% of patients 
(6). The bone marrow almost always 
will show a clonal population of plasma 
cells detectable by immunohistochem-
istry and immunoflourescence (7, 8). 
Direct biopsy of the affected organ will 
most likely be positive (9) although 
not usually needed (10). Radionuclide 
scans using radio labeled amyloid P 
component are capable of binding to 
amyloid deposits (11).
Clinical introduction
Fatigue, weight loss and periorbital pur-
pura are the most common presenting 
symptoms (10). Consequently, a large 
proportion of these patients undergo 
detailed searches for an underlying 
occult malignancy (1). Macroglossia, 
the most specific physical finding, is 
positive only 9% of the time.
The four most common “syndromes” 
in immunoglobulin amyloidosis are: 
nephrotic range proteinuria (12), con-
gestive heart failure (CHF) (5), unex-
plained hepatomegaly (13) and idio-
pathic peripheral neuropathy (14).
Kidney is the most frequently affected 
organ (35-50% patients) (15) usually pre-
senting as unexplained nephrotic syn-
drome (16). Renal amyloidosis is seen 
in 10% of renal biopsies of non diabetics 
with nephrotic syndrome (12).
Cardiac involvement is seen in 25% 
patients, usually with unexplained CHF. 
Restrictive cardiomyopathy is seen in 
late stages (5). There is no systolic dys-
function till late in the disease. Echocar-
diogram frequently shows diastolic dys-
function, septal thickness of >12 mm 
(88% patients) (17,18), ventricular wall 
thickness  >15 mm (19) and thicken-
ing of mitral and tricuspid valves. ECG 
usually shows low voltage (20) and QS 
complexes in leads V1 - V3 may be 
seen and interpreted falsely as a silent 
myocardial infarction (21).  
16-25% of patients have hepatome-
galy disproportionate to liver function 
tests abnormalities (22). Ascites is seen 
because of associated nephrotic syn-
drome and not due to portal hyper-
tension as patients die of extrahepatic 
amyloidosis before portal hypertension 
can develop. Cholestatic jaundice is 
usually a preterminal finding. (23,24). 
Salivary gland involvement can cause 
xerostomia (25,26).  Gastric amyloido-
sis with nausea, vomiting and weight 
loss was seen in 8 and gastroparesis 
was seen in 3 of 769 patients in one 
series (27). Less than 5% of patients 
will show malabsorption. Amyloidosis 
can rarely present as pseudo-obstruc-
tion or ischemic colitis (28,29). Luminal 
narrowing and loss of haustrations are 
the most common radiological findings 
(30).
Peripheral neuropathy, usually in the 
lower extremities, is seen in 17% of 
patients. Muscle weakness (from neu-
ropathy or vascular occlusion) and 
autonomic dysfunction are seen in 
approximately 65% of patients each. 
Muscle infiltration and pseudohypertro-
phy can be seen (31,32). Rarely tem-
poral artery involvement may mimic 
giant cell arteritis. Calf, limb and jaw 
claudication might be seen (33-35). 
Fragile infiltrated blood vessels cause 
purpura and bleeds.
The respiratory system and gas exc-
hange are usually preserved till late in 
the disease. Pulmonary amyloidosis 
may be localized or be a manifestation 
of systemic involvement. Local disease 
is classified as tracheobronchial, soli-
tary nodular, multiple nodular and dif-
fuse parenchymal (rare) (36). Patients 
may have dyspnea at rest or exertion 
and dry cough.  Chest X-ray (CXR) may 
have features of interstitial lung dis-
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ease. Amyloid deposits are seen on 
biopsy and may be predominant in the 
vascular walls or alveolar septa or both 
(37).      
Hematological abnormalities like factor 
X deficiency, prolonged prothrombin 
time, platelet defects, decreased alpha 
2 plasmin inhibitor, increased plas-
minogen may be seen (38,39). 
Pulmonary
hypertension
 A Mayo Clinic study has reported 5 
cases with the rare presentation of 
amyloidosis and pulmonary hyperten-
sion (PH) in patients with no secondary 
cause for PH and no evidence of left 
ventricle dysfunction. PH was found a 
median 73 days before death (2).
In patients with diffuse pulmonary amy-
loidosis, PH can be caused by either 
severe vessel wall infiltration with amy-
loid or by amyloid deposition in the 
alveolar septa, causing obliteration of 
a significant proportion of the pulmo-
nary capillary bed and pulmonary HTN 
developing concurrently with lung vol-
ume restriction (40). 
Prognosis
Cardiac disease is the most relevant 
prognostic factor (41-43). 50% of patients 
will die of cardiac causes – CHF, ven-
tricular fibrillation or asystole (44). A bad 
prognosis is seen in patients with EF < 
50%, Creatinine > 1.3, neuropathy and 
diastolic dysfunction.
Therapy
Despite therapy, the median survival is 
only 17 months after diagnosis. In com-
parison, good-responders to treatment 
survive a median 90 months (6). Cycles 
of mephalan and prednisone are the 
treatment of choice (45). Response 
is measured by a 50% reduction in 
either urinary protein excretion or M-
component or light chain or amyloid 
precursor protein or serum alkaline 
phosphatase or a 2 mm reduction in 
cardiac wall thickness. Approximately 
6.5% of patients exposed to melphalan 
develop a myelodysplastic syndrome. 
Median survival from onset is 8 months. 
Heart transplantation is effective for 
amyloidosis (46,47) with reported sur-
vival of 69-118 months. Myeloablative 
therapy with stem cell reconstitution 
(48) could work but has a treatment 
related mortality of 30-40% (49). 
Conclusion
Amyloidosis should be considered in 
patients older than 40 years who have 
unexplained nephrotic syndrome, heart 
failure, idiopathic peripheral neuropa-
thy or hepatomegaly. Diffuse pulmo-
nary amyloidosis should be consid-
ered in the differential of unexplained 
pulmonary hypertension, especially in 
patients with systemic amloidosis or 
multiple myeloma.
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